Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
复制标题
DOI：
10.3390/ijms19103258
复制
发表时间：
2018-10-20
影响因子：
5.6
通讯作者：
Wehland M
中科院分区：
文献类型：
--
作者：
Milling RV;Grimm D;Krüger M;Grosse J;Kopp S;Bauer J;Infanger M;Wehland M
甲状腺髓样癌是一种罕见的恶性肿瘤，预后差。一线治疗是手术，这是唯一的治愈方法的疾病。然而，在不可手术的情况下或肿瘤进展和转移，全身治疗是必要的。这种形式的癌症通常对常规化疗不敏感，但使用酪氨酸激酶抑制剂（TKI），如帕唑帕尼，卡博替尼和凡德他尼，已显示出有希望的结果，增加了无进展生存期和延长了寿命。因此，我们重点关注TKI的药理学特征、其作用机制、其作为MTC的二级治疗选择的应用、其作为癌症药物治疗的疗效，并回顾了正在进行的临床试验。TKI也会全身性作用，导致各种不良事件（AE）。这种治疗的一种常见AE是高血压，已知与心血管疾病相关，因此可能会使接受治疗的患者的健康状况恶化。对药物性高血压的有效治疗策略进行了讨论。高血压发生的机制尚不清楚。因此，该AE的治疗仍为对症治疗。因此，未来的研究是必要的，以调查肿瘤生长抑制和高血压之间的联系。此外，应实施优化的个体化治疗策略。
Medullary thyroid cancer (MTC) is a rare malignancy with a poor prognosis. First line therapy is surgery, which is the only curative method of the disease. However, in non-operable cases or with tumor progression and metastases, a systemic treatment is necessary. This form of cancer is often insensitive to conventional chemotherapy, but the use of tyrosine kinase inhibitors (TKIs), such as pazopanib, cabozantinib, and vandetanib, has shown promising results with an increase in progression-free survival and prolonged lifetime. Therefore, we focused on the pharmacological characteristics of TKIs, their mechanism of action, their application as a secondary treatment option for MTC, their efficacy as a cancer drug treatment, and reviewed the ongoing clinical trials. TKIs also act systemically causing various adverse events (AEs). One common AE of this treatment is hypertension, known to be associated with cardiovascular disease and can therefore potentially worsen the well-being of the treated patients. The available treatment strategies of drug-induced hypertension were discussed. The mechanism behind the development of hypertension is still unclear. Therefore, the treatment of this AE remains symptomatic. Thus, future studies are necessary to investigate the link between tumor growth inhibition and hypertension. In addition, optimized, individual treatment strategies should be implemented.
登录
查看更多内容
影响因子：
9.8
作者：
Kruzliak, Peter;Kovacova, Gabriela;Pechanova, Olga
通讯作者：
Pechanova, Olga
DOI：
10.1161/01.atv.17.11.2793
发表时间：
1997-11-01
影响因子：
8.7
作者：
Horowitz, JR;Rivard, A;Isner, JM
通讯作者：
Isner, JM
DOI：
10.1158/1078-0432.ccr-13-0071
发表时间：
2013-08-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Fox E;Widemann BC;Chuk MK;Marcus L;Aikin A;Whitcomb PO;Merino MJ;Lodish M;Dombi E;Steinberg SM;Wells SA;Balis FM
通讯作者：
Balis FM
影响因子：
2.9
作者：
Linh Nguyen;Holland, Jaymes;Lacy, Steven
通讯作者：
Lacy, Steven
影响因子：
5.7
作者：
Kumar, Rakesh;Knick, Victoria B.;Cheung, Mui
通讯作者：
Cheung, Mui